Considering that higher BCL2 levels are associated with sensitivity to ABT-199 in other cancers [12,13,14], these data provide a rationale for testing the efficacy of BCL2 inhibitors, such as ABT-199 (venetoclax), in patients with BRAF-WT melanomas. The gene discussed is BRAF; the disease is melanoma.